Crizotinib, an approved treatment for advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC), did not improve disease-free survival (DFS) when given as adjuvant therapy in patients with ...
Crizotinib and entrectinib are both active against ROS1+ non-small cell lung cancer. But which is best? The answer seems easy: Just compare the drugs' clinical trial results. However, not all trials ...
Discover comprehensive details about Crizotinib, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...
October 27, 2010 — Striking activity reported for the oral investigational drug crizotinib (Pfizer) in tumors that harbor a specific mutant protein has prompted a New England Journal of Medicine ...
Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–rearranged ...
Adjuvant crizotinib (Xalkori) failed to improve disease-free survival (DFS) in patients with surgically resected early-stage ALK-positive non-small cell lung cancer (NSCLC), the phase III ECOG-ACRIN ...
Treatment with the targeted therapy drug crizotinib effectively halted the growth of lung tumors driven by rearrangements of the ROS1 gene in a small clinical trial. Treatment with the targeted ...
Doctors are reluctant to read too much into promising results from small clinical trials of cancer drugs. No point getting excited when so often drugs don’t look as hot after being tested in a larger ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results